No Detail Found!

The effect of Tocilizumab on Inflammatory Markers in Survivors and Non-survivors of Severe COVID-19

Author(s)
Said Amin Department of Medicine, Hayatabad Medical Complex,Peshawar,Pakistan
Fawad Rahim Department of Medicine, Hayatabad Medical Complex,Peshawar,Pakistan
Sher Bahadur Department of Research, Khyber Institute of Child Health,Hayatabad, Peshawar,Pakistan
Mohammad Noor Department of Medicine, Hayatabad Medical Complex,Peshawar,Pakistan
Afsheen Mahmood Department of Physiology, Khyber Girls Medical College,Peshawar,Pakistan
Huma Gul Department of Pharmacology, Khyber Girls Medical College,Peshawar,Pakistan
Abstract
Objective: To determine the e ects of tocilizumab (TCZ) on in ammatory markers, laboratory indices; and short-term outcome in patients with severe COVID-19. Study Design: Cross-sectional analytical study. Place and Duration of the Study: Hayatabad Medical Complex, Peshawar, Pakistan from 10th June till 31st August 2020. Methodology: Fifty-four patients with severe COVID-19 ful lled the inclusion criteria and were included. All patients had received TCZ (4 mg/kg) in addition to standard treatment. Serum C-reactive protein (CRP), lactate dehydrogenase (LDH), Ddimer levels, full blood count, and liver function tests (LFTs) were checked before and 24 hours after receiving TCZ. Short-term outcome, de ned as survival at day 28, was determined from hospital record/telephonic contact. Paired t-test was employed to assess the statistical signi cance of mean di erences between the pre- and post-TCZ variables, considering a p-value of <0.05 as signi cant. Results: Overall, the mean pre- and post-TCZ CRP was 18.7 ± 10.7 and 10.2 ± 8.6 mg/dl (p <0.001). It was 18.0 ± 10.3 and 10.3 ± 8.8 mg/dl (p=0.003) in survivors; and 19.4 ± 11.4 and 10.2 ± 8.7 mg/dl (p=0.005) in non-survivors, respectively. Overall, mean D-dimer level decreased from 12.5 ± 23 to 10.3 ± 12.2 µg/ml following TCZ (p=0.643); it decreased from 15.8 ± 29.8 to 11.4 ± 10.6 µg/ml (p=0.612) in survivors; and 9.0 ± 12.8 to 9.2 ± 14.1 µg/ml (p=0.961) in non-survivors, respectively. There were no signi cant di erences in the pre- and post-TCZ LDH levels overall and between the groups. The 28-day mortality was 46.3%. Conclusion: Tocilizumab results in a signi cant reduction in CRP, while mean change in LDH and D-dimers was not substantial. The mean change in in ammatory markers did not predict survival.
Publication Details
Page(s) 7-10
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: S2, Year: 2021

Request the full text from PASTIC

Keywords
Mortality, Outcome, biomarkers, COVID-19, Tocilizumab
0

Citations

0

Downloads

130

Views